Amneal Pharmaceuticals, Inc. Stock News

Amneal Pharmaceuticals Inc:

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), a New Jersey-based pharmaceutical company, today announced that its product RYANODEX® (dantrolene sodium) for injectable suspension inhibited the

Bank of America Corp DE raised its holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 205.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fu

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that its 2020 Annual Meeting of Stockholders (the "Annual Meeting") will be a virtual meeting instead of an in-per

Bank of New York Mellon Corp lifted its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 147.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The instituti

Amneal Pharmaceuticals (NYSE:AMRX) may soon run out of the raw ingredients to make hydroxychloroquine because Finland is keeping the drug for domestic use, the company's co-CEOs tell Reuters.Amneal ha

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) shareholders should be happy to see the share price up 16% in the last month...

Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is

Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is

Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the antimalarial drug hydroxychloroquine that has been touted as a potential treatment for COVID-19 because Finland is

Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) dropped 7.3% during trading on Tuesday . The company traded as low as $2.86 and last traded at $2.91, approximately 2,324,233 shares traded hands durin

Amneal Pharmaceuticals Inc (NYSE:AMRX) has been assigned an average recommendation of “Hold” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. Two investment anal

Several pharmaceutical companies stand to profit from the drug's promotion, including shareholders and senior executives with connections to the president.

SVB Leerink analyst Ami Fadia says the pandemic could bring some relief to beaten-down generic-drug companies.